Researchers at UC San Diego have been awarded a DARPA contract to redesign red blood cells to temporarily boost human performance.

Immunotherapy for gynecological tumors is in a period of rapid development, bringing new hope to patients but also facing some new problems. How to achieve better clinical translation and improve treatment strategies based on current experimental research requires our joint efforts.

Hepatocellular carcinoma (HCC) typically develops in chronically inflamed and cirrhotic livers, where malignant hepatocytes are continuously exposed to immune pressure. Although cytotoxic immunity is essential for tumor control, persistent immune activation may paradoxically enable cancer cells to acquire adaptive traits that support disease progression. How this chronic immune pressure contributes to the initiation of metastasis in HCC, however, remains poorly understood.

BUFFALO, NY – August 28, 2026 – A new research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled “Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.”

James Weger-Lucarelli, associate professor in the Department of Biomedical Sciences and Pathobiology at the Virginia-Maryland College of Veterinary Medicine, received a five-year, $2.01 million award from the National Institute of General Medical Sciences in July to investigate how infected cells live and die, and what they signal to their neighbors when they do. The grant could eventually point toward better antiviral drugs and more effective virus-based cancer treatments.

In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the genetic aberrations and microenvironmental peculiarities of tumors and their constituent cells.